Application of biochemical markers in development of drugs for treatment of osteoarthritis

References

• Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De PL, Vanhaelst L and Reginster JY. (2004). Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 12:263–8.
   PubMed Web of Science ®Google Scholar
• Abramson S, Krasnokutsky S. (2006). Biomarkers in osteoarthritis. Bull NYU Hosp Jt Dis 64:77–81.
   PubMedGoogle Scholar
• Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. (1997). Influence of osteoarthritis on serum marker levels of bone formation and resorption in patients with benign prostatic hypertrophy. Int J Urol 4:580–2.
   PubMedGoogle Scholar
• Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana J, Egido J and Largo R. (2008). Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 16:1484–93.
   PubMed Web of Science ®Google Scholar
• Andersson ML, Thorstensson CA, Roos EM, Petersson IF, Heinegard D, Saxne T. (2006). Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC Musculoskelet Disord 7:98.
   PubMed Web of Science ®Google Scholar
• Archer CW, Francis-West P. (2003). The chondrocyte. Int J Biochem Cell Biol 35:401–4.
   PubMed Web of Science ®Google Scholar
• Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegard D, Jordan JM, Kepler TB, Lane NE. (2006). Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14:723–7.
   PubMed Web of Science ®Google Scholar
• Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. (2005). Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 64:1263–7.
   PubMed Web of Science ®Google Scholar
• Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. (2002). Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46:3178–84.
   PubMed Web of Science ®Google Scholar
• Bevilacqua M, Devogelaer JP, Righini V, Famaey JP, Manicourt DH. (2004). Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. Int J Clin Pract Suppl 13–19.
   PubMedGoogle Scholar
• Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, Wart HV, Poole AR. (1997). Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 99:1534–45.
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. (2006). Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54:3494–507.
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Christiansen C. (2000). Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26:561–9.
   PubMed Web of Science ®Google Scholar
• Bondeson J, Wainwright S, Hughes C, Caterson B. (2008). The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 26:139–45.
   PubMed Web of Science ®Google Scholar
• Brune K, Katus HA, Moecks J, Spanuth E, Jaffe AS, Giannitsis E. (2008). N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. Clin Chem 54:1149–57.
   PubMed Web of Science ®Google Scholar
• Chaganti RK, Kelman A, Lui L, Yao W, Javaid MK, Bauer D, Nevitt M, Lane NE;Study of Osteoporotic Fractures Research Group Sof. (2008). Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis. Osteoarthritis Cartilage 16:566–71.
   PubMed Web of Science ®Google Scholar
• Charni N, Desmarais S, Bay-Jensen A, Delaisse JM, Percival MD, Garnero P. (2008). The type II collagen fragments Helix-II and CTX-II reveal distinct enzymatic pathways of cartilage collagen degradation. Osteoarthritis Cartilage 16:1183–91.
   PubMed Web of Science ®Google Scholar
• Charni-Ben TN, Richardot P, Toh L, Marotte H, Bay-Jensen AC, Miossec P, Garnero P. (2009). Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis. Ann Rheum Dis 68:451–2.
   PubMed Web of Science ®Google Scholar
• Chopin F, Garnero P, le HA, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T. (2008). Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353–7.
   PubMed Web of Science ®Google Scholar
• Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C, Qvist P. (2001). Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29:209–15.
   PubMed Web of Science ®Google Scholar
• Christgau S, Henrotin Y, Tanko LB, Rovati LC, Collette J, Bruyere O, Deroisy R, Reginster JY. (2004). Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 22:36–42.
   PubMed Web of Science ®Google Scholar
• Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, Ionescu M, Poole AR, Esdaile JM. (2005). Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 32: 896–902.
   PubMed Web of Science ®Google Scholar
• Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou S, Munk PL, Esdaile JM. (2009). Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 60:1372–80.
   PubMed Web of Science ®Google Scholar
• Cicuttini FM, Jones G, Forbes A, Wluka AE. (2004). Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann Rheum Dis 63:1124–7.
   PubMed Web of Science ®Google Scholar
• Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, Kraus VB. (1999). Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 42:2356–64.
   PubMed Web of Science ®Google Scholar
• Conrozier T, Saxne T, Fan CS, Mathieu P, Tron AM, Heinegard D, Vignon E. (1998). Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis 57:527–32.
   PubMed Web of Science ®Google Scholar
• Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. (2009). Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 17:384–9.
   PubMed Web of Science ®Google Scholar
• Deberg M, Dubuc JE, Labasse A, Sanchez C, Quettier E, Bosseloir A, Crielaard JM and Henrotin Y. (2008). One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 67:168–74.
   PubMed Web of Science ®Google Scholar
• Deberg MA, Labasse AH, Collette J, Seidel L, Reginster JY, Henrotin YE. (2005). One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 13:1059–65.
   PubMed Web of Science ®Google Scholar
• Dejica VM, Mort JS, Laverty S, Percival MD, Antoniou J, Zukor DJ, Poole AR. (2008). Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol 1:161–9.
   Google Scholar
• Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, Mezes PS, Pelletier JP, Otterness IG. (2001). Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 247:25–34.
   PubMed Web of Science ®Google Scholar
• Drees P, Decking J, Ghezel-Ahmadi V, Delank KS, Wilhelm B, Eckardt A. (2005). [The common occurrence of osteoarthritis and osteoporosis and the value of markers of bone turnover]. Z Rheumatol 64:488–98.
   PubMed Web of Science ®Google Scholar
• Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, Dragomir AD, Helmick CG, Hochberg MC, Jordan JM. (2005). Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 52:105–11.
   PubMed Web of Science ®Google Scholar
• Elomaa I, Virkkunen P, Risteli L, Risteli J. (1992). Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66:337–41.
   PubMed Web of Science ®Google Scholar
• Emrani PS, Katz JN, Kessler CL, Reichmann WM, Wright EA, McAlindon TE, Losina E. (2008). Joint space narrowing and Kellgren–Lawrence progression in knee osteoarthritis: an analytic literature synthesis. Osteoarthritis Cartilage 16:873–82.
   PubMed Web of Science ®Google Scholar
• Eyre DR, Weis MA. (2009). The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. Osteoarthritis Cartilage 17:423–6.
   PubMed Web of Science ®Google Scholar
• Felson DT. (2004). An update on the pathogenesis and epidemiology of osteoarthritis 17. Radiol Clin North Am 42:1–9, v.
   PubMed Web of Science ®Google Scholar
• Felson DT, Neogi T. (2004). Osteoarthritis: is it a disease of cartilage or of bone? 21. Arthritis Rheum 50:341–4.
   PubMed Web of Science ®Google Scholar
• Fex E, Eberhardt K, Saxne T. (1997). Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Br J Rheumatol 36:1161–5.
   PubMedGoogle Scholar
• Forsblad dH, Christgau S, Mattsson LA, Saxne T, Ohlsson C, Nordborg E, Carlsten H. (2004). Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]. Arthritis Res Ther 6:R457–R468.
   Web of Science ®Google Scholar
• Fosang AJ, Stanton H, Little CB, Atley LM. (2003). Neoepitopes as biomarkers of cartilage catabolism. Inflamm Res 52:277–82.
   PubMed Web of Science ®Google Scholar
• Garnero P. (2006a). Biochemical markers in osteoarthritis: will they measure up? Nat Clin Pract Rheumatol 2:116–17.
   PubMedGoogle Scholar
• Garnero P. (2006b). Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 8:37–44.
   PubMedGoogle Scholar
• Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham CO III. (2008a). Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 16:660–6.
   PubMed Web of Science ®Google Scholar
• Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD. (2002). Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46:2613–24.
   PubMed Web of Science ®Google Scholar
• Garnero P, Borel O, Delmas PD. (2001a). Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694–702.
   PubMed Web of Science ®Google Scholar
• Garnero P, Dargent-Molina P, Hans D, Schott AM, Breart G, Meunier PJ, Delmas PD. (1998). Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563–9.
   PubMed Web of Science ®Google Scholar
• Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM. (2003). The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–67.
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. (1996). Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–8.
   PubMed Web of Science ®Google Scholar
• Garnero P, Mazieres B, Gueguen A, Abbal M, Berdah L, Lequesne M, Nguyen M, Salles JP, Vignon E, Dougados M. (2005a). Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 32:697–703.
   PubMed Web of Science ®Google Scholar
• Garnero P, Peterfy C, Zaim S, Schoenharting M. (2005b). Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 52:2822–9.
   PubMed Web of Science ®Google Scholar
• Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. (2001b). Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 60:619–26.
   PubMed Web of Science ®Google Scholar
• Garnero P, Rousseau J-C, Delmas PD. (2000a). Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 43:953–68.
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. (2000b). Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–36.
   PubMed Web of Science ®Google Scholar
• Garnero P, Vergnaud P, Hoyle N. (2008b). Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188–96.
   PubMed Web of Science ®Google Scholar
• Gendron C, Kashiwagi M, Lim NH, Enghild JJ, Thogersen IB, Hughes C, Caterson B, Nagase H. (2007). Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 282:18294–306.
   PubMed Web of Science ®Google Scholar
• Georges C, Vigneron H, Ayral X, Listrat V, Ravaud P, Dougados M, Sharif M, Dieppe P, Saxne T. (1997). Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. Arthritis Rheum 40:590–1.
   PubMedGoogle Scholar
• Gineyts E, Garnero P and Delmas PD. (2001). Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology (Oxford) 40:315–23.
   PubMed Web of Science ®Google Scholar
• Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, Garnero P, Delmas PD. (2004). Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 63:857–61.
   PubMed Web of Science ®Google Scholar
• Glant TT, Mikecz K, Roughley PJ, Buzas E, Poole AR. (1986). Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. Biochem J 236:71–5.
   PubMed Web of Science ®Google Scholar
• Goldring SR. (2009). Role of bone in osteoarthritis pathogenesis. Med Clin North Am 93:25–35, xv.
   PubMed Web of Science ®Google Scholar
• Gressner OA, Weiskirchen R, Gressner AM. (2007). Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 11:1031–51.
   PubMed Web of Science ®Google Scholar
• Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. (1992). A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251–8.
   PubMed Web of Science ®Google Scholar
• Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, Rodan GA, Duong le T. (2004). The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50:1193–206.
   PubMed Web of Science ®Google Scholar
• Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong le T. (2006). Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 38:234–43.
   PubMed Web of Science ®Google Scholar
• Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ. (2006). Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 14:1189–95.
   PubMed Web of Science ®Google Scholar
• Henrotin Y, Addison S, Kraus V, Deberg M. (2007). Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 19:444–50.
   PubMed Web of Science ®Google Scholar
• Henrotin Y, Deberg M, Dubuc JE, Quettier E, Christgau S, Reginster JY. (2004). Type II collagen peptides for measuring cartilage degradation. Biorheology 41:543–7.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, LaValley M, Li J, Bauer DC, Nevitt M, DeGroot J, Poole R, Eyre D, Guermazi A, Gale D, Totterman S, Felson DT. (2008). Biochemical markers of bone turnover and their association with bone marrow lesions. Arthritis Res Ther 10:R102.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Li J, LaValley M, Bauer DC, Nevitt M, DeGroot J, Poole R, Eyre D, Guermazi A, Gale D, Felson DT. (2007). Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 9:R108.
   PubMed Web of Science ®Google Scholar
• Hunter DJ and Spector TD. (2003). The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep 5:15–19.
   PubMedGoogle Scholar
• Hurter K, Spreng D, Rytz U, Schawalder P, Ott-Knusel F, Schmokel H. (2005). Measurements of C-reactive protein in serum and lactate dehydrogenase in serum and synovial fluid of patients with osteoarthritis. Vet J 169:281–5.
   PubMed Web of Science ®Google Scholar
• Jansen NW, Roosendaal G, Lundin B, Heijnen L, Mauser-Bunschoten E, Bijlsma JW, Theobald M, Lafeber FP. (2009). The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 60:290–8.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Jensen HS, Price PA. (1993). A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 32:949–55.
   PubMedGoogle Scholar
• Jordan JM, Luta G, Stabler T, Renner JB, Dragomir AD, Vilim V, Hochberg MC, Helmick CG, Kraus VB. (2003). Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum 48:675–81.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Syddall HE, Garnero P, Gineyts E, Dennison EM, Sayer AA, Delmas PD, Cooper C, Arden NK. (2006). Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 65:871–7.
   PubMed Web of Science ®Google Scholar
• Jung M, Christgau S, Lukoschek M, Henriksen D, Richter W. (2004). Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 71:70–6.
   PubMed Web of Science ®Google Scholar
• Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K. (2004). Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis. Ann Clin Lab Sci 34:330–5.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, Altman RD, Christiansen C. (2008). Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 16:638–46.
   PubMed Web of Science ®Google Scholar
• Kellgren JH, Lawrence JS. (1957). Radiological assessment of rheumatoid arthritis. Ann Rheum Dis 16:485–93.
   PubMed Web of Science ®Google Scholar
• Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Ito S, Suguro T, Sumida T. (2008). Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol 18:15–22.
   PubMed Web of Science ®Google Scholar
• Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. (2006). Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 54:2496–504.
   PubMed Web of Science ®Google Scholar
• Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E. (2007). Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178:849–53.
   PubMed Web of Science ®Google Scholar
• Krasnokutsky S, Samuels J, Abramson SB. (2007). Osteoarthritis in 2007. Bull NYU Hosp Jt Dis 65:222–8.
   PubMedGoogle Scholar
• Kraus VB. (2006). Do biochemical markers have a role in osteoarthritis diagnosis and treatment? Best Pract Res Clin Rheumatol 20:69–80.
   PubMed Web of Science ®Google Scholar
• Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, Beary J, Aronstein WS, Spector TD. (2007). Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 9:R109.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. (2006). The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32–8.
   PubMed Web of Science ®Google Scholar
• Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, Jung K. (2009). Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate69:624–32.
   PubMed Web of Science ®Google Scholar
• Li MG, Thorsen K, Nilsson KG. (2004). Increased bone turnover as reflected by biochemical markers in patients with potentially unstable fixation of the tibial component. Arch Orthop Trauma Surg 124:404–9.
   PubMed Web of Science ®Google Scholar
• Lohmander LS, Atley LM, Pietka TA, Eyre DR. (2003). The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 48:3130–9.
   PubMedGoogle Scholar
• Lohmander LS, Brandt KD, Mazzuca SA, Katz BP, Larsson S, Struglics A, Lane KA. (2005). Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 52:3160–7.
   PubMed Web of Science ®Google Scholar
• Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. (2006). Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54:3205–11.
   PubMed Web of Science ®Google Scholar
• Manicourt DH, Bevilacqua M, Righini V, Famaey JP, Devogelaer JP. (2005). Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D 6:261–71.
   PubMedGoogle Scholar
• Marotte H, Gineyts E, Miossec P, Delmas PD. (2008). Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 68:1197–200.
   PubMed Web of Science ®Google Scholar
• Mazieres B, Garnero P, Gueguen A, Abbal M, Berdah L, Lequesne M, Nguyen M, Salles JP, Vignon E, Dougados M. (2006). Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 65:354–9.
   PubMed Web of Science ®Google Scholar
• Mazieres B, Hucher M, Zaim M, Garnero P. (2007). Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 66:639–45.
   PubMed Web of Science ®Google Scholar
• Mazzuca SA, Poole AR, Brandt KD, Katz BP, Lane KA, Lobanok T. (2006). Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 33:1147–51.
   PubMed Web of Science ®Google Scholar
• Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. (1996). Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947–54.
   PubMed Web of Science ®Google Scholar
• Melkko J, Niemi S, Risteli L, Risteli J. (1990). Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36:1328–32.
   PubMed Web of Science ®Google Scholar
• Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio Le Graverand MP, DeGroot J, Slagboom PE. (2006). Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 65:360–5.
   PubMed Web of Science ®Google Scholar
• Miller GD, Nicklas BJ, Davis CC, Ambrosius WT, Loeser RF, Messier SP. (2004). Is serum leptin related to physical function and is it modifiable through weight loss and exercise in older adults with knee osteoarthritis? Int J Obes Relat Metab Disord 28:1383–90.
   PubMed Web of Science ®Google Scholar
• Miller GD, Nicklas BJ, Loeser RF. (2008). Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intensive weight-loss therapy. J Am Geriatr Soc 56:644–51.
   PubMed Web of Science ®Google Scholar
• Millward-Sadler SJ, Salter DM. (2004). Integrin-dependent signal cascades in chondrocyte mechanotransduction. Ann Biomed Eng 32:435–46.
   Google Scholar
• Murphy G, Nagase H. (2008). Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 4:128–35.
   PubMedGoogle Scholar
• Nagase H, Kashiwagi M. (2003). Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 5:94–103.
   PubMed Web of Science ®Google Scholar
• Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, Fraser GL, Brooks E, Tanzer M, Rosenberg LC, Dieppe P, Robin PA. (1998). Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 102:2115–25.
   PubMed Web of Science ®Google Scholar
• Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, Hein GE, Karsdal MA, Qvist P. (2007). Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 15:335–42.
   PubMed Web of Science ®Google Scholar
• Otterness IG, Brandt KD, Le Graverand MP, Mazzuca SA. (2007). Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing. Arthritis Rheum 56:3644–9.
   PubMedGoogle Scholar
• Pearle AD, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, Sculco TP, Crow MK. (2007). Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 15:516–23.
   PubMed Web of Science ®Google Scholar
• Penninx BW, Abbas H, Ambrosius W, Nicklas BJ, Davis C, Messier SP, Pahor M. (2004). Inflammatory markers and physical function among older adults with knee osteoarthritis. J Rheumatol 31:2027–31.
   PubMed Web of Science ®Google Scholar
• Pessis E, Drape JL, Ravaud P, Chevrot A, Dougados M, Ayral X. (2003). Assessment of progression in knee osteoarthritis: results of a 1 year study comparing arthroscopy and MRI. Osteoarthritis Cartilage 11:361–9.
   PubMed Web of Science ®Google Scholar
• Peterfy CG, Guermazi A, Zaim S, Tirman PF, Miaux Y, White D, Kothari M, Lu Y, Fye K, Zhao S, Genant HK. (2004). Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 12:177–90.
   PubMed Web of Science ®Google Scholar
• Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. (2004). The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 294:145–53.
   PubMed Web of Science ®Google Scholar
• Popko J, Zalewska A, Sierakowski S, Macias T, Knas M, Zwierz K, Sredzinska K. (2005). [Activity of N-acetylo-beta-hexosamninidase in joint fluid from knee and serum of patients with rheumatoid arthritis and osteoarthritis]. Przegl Lek 62:650–2.
   PubMedGoogle Scholar
• Pratta MA, Su JL, Leesnitzer MA, Struglics A, Larsson S, Lohmander LS, Kumar S. (2006). Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 14:702–13.
   PubMed Web of Science ®Google Scholar
• Pulai JI, Chen H, Im HJ, Kumar S, Hanning C, Hegde PS, Loeser RF. (2005). NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 174:5781–8.
   PubMed Web of Science ®Google Scholar
• Quintana DJ, Garnero P, Huebner JL, Charni-Ben TN, Kraus VB. (2008). PIIANP and HELIXII diurnal variation. Osteoarthritis Cartilage 16:1192–5.
   PubMed Web of Science ®Google Scholar
• Qvist P, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, Karsdal MA. (2008). The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res 58:1–7.
   PubMed Web of Science ®Google Scholar
• Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. (2002). Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61.
   PubMed Web of Science ®Google Scholar
• Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA. (2004). A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50:2471–8.
   PubMed Web of Science ®Google Scholar
• Richardot P, Charni-Ben Tabassi N, Toh L, Marotte H, Bay-Jensen AC, Miossec P, Garnero P. (2009). Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Osteoarthritis Cartilage May 12 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. (1988). Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 34:715–18.
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. (1998). Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281–9.
   PubMed Web of Science ®Google Scholar
• Rousseau JC and Delmas PD. (2007). Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 3:346–56.
   PubMedGoogle Scholar
• Rousseau JC, Sandell LJ, Delmas PD, Garnero P. (2004a). Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. Methods Mol Med 101:25–37.
   PubMedGoogle Scholar
• Rousseau JC, Sumer EU, Hein G, Sondergaard BC, Madsen S, Pedersen C, Neumann T, Mueller A, Qvist P, Delmas P, Karsdal MA. (2008). Patients with Rheumatoid Arthritis have an altered circulatory Aggrecan Profile. BMC Musculoskelet Disord 9:74.
   PubMed Web of Science ®Google Scholar
• Rousseau J-C, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, Delmas PD. (2004b). Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 12:440–7.
   PubMed Web of Science ®Google Scholar
• Ryu J, Towle CA and Treadwell BV. (1982). Characterisation of human articular cartilage link proteins from normal and osteoarthritic cartilage. Ann Rheum Dis 41:164–7.
   PubMed Web of Science ®Google Scholar
• Salminen-Mankonen HJ, Morko J, Vuorio E. (2007). Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 8:315–23.
   PubMed Web of Science ®Google Scholar
• Samuels J, Krasnokutsky S, Abramson SB. (2008). Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 66:244–50.
   PubMedGoogle Scholar
• Sandy JD. (2006). A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 14:95–100.
   PubMed Web of Science ®Google Scholar
• Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J. (2000). Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367–73.
   PubMed Web of Science ®Google Scholar
• Saxne T, Heinegard D. (1992). Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31:583–91.
   PubMedGoogle Scholar
• Scanzello CR, Umoh E, Pessler F, az-Torne C, Miles T, Dicarlo E, Potter HG, Mandl L, Marx R, Rodeo S, Goldring SR, Crow MK. (2009). Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage 17:1040–8.
   PubMed Web of Science ®Google Scholar
• Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, Qvist P, Karsdal MA. (2005). In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3:553–80.
   PubMed Web of Science ®Google Scholar
• Schmidt-Rohlfing B, Thomsen M, Niedhart C, Wirtz DC, Schneider U. (2002). Correlation of bone and cartilage markers in the synovial fluid with the degree of osteoarthritis. Rheumatol Int 21:193–9.
   PubMed Web of Science ®Google Scholar
• Sennels H, Sorensen S, Ostergaard M, Knudsen L, Hansen M, Skjodt H, Peters N, Colic A, Grau K, Jacobsen S. (2008). Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 37:241–7.
   PubMed Web of Science ®Google Scholar
• Sharaki OA, El-Guiziry DA, bou-Zeid AA, El-Noueam KI, Helal AE, Gaballah AE. (2004). Clinical usefulness of basic fibroblast growth factor and E-selectin in patients with rheumatoid arthritis. Egypt J Immunol 11:91–100.
   PubMedGoogle Scholar
• Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P. (2007). A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis–association with disease progression. Rheumatology (Oxford) 46:938–43.
   PubMed Web of Science ®Google Scholar
• Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegard D, Dieppe PA. (1995). Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 34:306–10.
   PubMedGoogle Scholar
• Shen H, Sprott H, Aeschlimann A, Gay RE, Michel BA, Gay S, Sprott H. (2006). Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. Rheumatology 45:765–70.
   PubMed Web of Science ®Google Scholar
• Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM. (2005). Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 7:R625–R633.
   PubMed Web of Science ®Google Scholar
• Spector TD, Reneland RH, Mah S, Valdes AM, Hart DJ, Kammerer S, Langdown M, Hoyal CR, Atienza J, Doherty M, Rahman P, Nelson MR, Braun A. (2006). Association between a variation in LRCH1 and knee osteoarthritis: a genome-wide single-nucleotide polymorphism association study using DNA pooling. Arthritis Rheum 54:524–32.
   PubMedGoogle Scholar
• Sugimoto H, Yamada H, Terada N, Kanaji A, Kato S, Date H, Ichinose H, Miyazaki K. (2006). Intraarticular injection of high molecular weight hyaluronan for osteoarthritis of the knee - prediction of effectiveness with biological markers. J Rheumatol 33:2527.
   PubMed Web of Science ®Google Scholar
• Sumer EU, Schaller S, Sondergaard BC, Tanko LB, Qvist P. (2006). Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 11:485–506.
   PubMed Web of Science ®Google Scholar
• Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, Christiansen C, Qvist P. (2007). MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 15:212–21.
   PubMed Web of Science ®Google Scholar
• Valdes AM, Doherty M, Spector TD. (2008). The additive effect of individual genes in predicting risk of knee osteoarthritis. Ann Rheum Dis 67:124–7.
   PubMed Web of Science ®Google Scholar
• Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP. (2006). Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 8:R31.
   PubMed Web of Science ®Google Scholar
• Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. (2002). Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 10:707–13.
   PubMed Web of Science ®Google Scholar
• Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. (2006). Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 95:506–14.
   PubMed Web of Science ®Google Scholar
• Wilkinson JM, Stockley I, Hamer AJ, Barrington NA, Eastell R. (2003). Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. J Orthop Res 21:529–34.
   PubMed Web of Science ®Google Scholar
• Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. (2004). How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis 63:264–8.
   PubMed Web of Science ®Google Scholar
• Xu L, Peng H, Glasson S, Lee PL, Hu K, Ijiri K, Olsen BR, Goldring MB, Li Y. (2007). Increased expression of the collagen receptor discoidin domain receptor 2 in articular cartilage as a key event in the pathogenesis of osteoarthritis. Arthritis Rheum 56:2663–73.
   PubMedGoogle Scholar
• Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, Duffin KL. (2008). Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 58:2420–31.
   PubMed Web of Science ®Google Scholar